Skip to main navigation Overview Stock Information News & Events Financials Governance Investor Resources Investor Relations Corporate Profile Harmony Biosciences is a U.S. commercial-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for people living with rare neurological disorders who have unmet medical needs. Established by founder Paragon Biosciences LLC, our mission is to positively impact the lives of those living with rare diseases who are so often underserved. In August of 2019, Harmony Biosciences received FDA approval for its first commercial product, WAKIX® (pitolisant) tablets. Harmony is currently evaluating pitolisant for broader applications in neurological disorders that may be mediated by the H3 receptor. See product pipeline for further details. NASDAQ: HRMY $37.92 +0.96 (+2.60%) Data Provided by Refinitiv. Minimum 15 minutes delayed. News Releases Harmony Biosciences Appoints Linda Szyper To Its Board Of Directors Nov 22, 2021 PLYMOUTH MEETING, Pa. , Nov. 22, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced the View All News View All Events More events are coming soon. View All Events View All Contact Information ir@harmonybiosicences.com Site - Shareholder Tools Print Page Email Alerts RSS Contact IR Copyright © 2021 Harmony Biosciences All rights reserved.